定义系统化疗在局部和高级尾腺癌中的作用
M C Strach1, B Chakrabarty2, R T Nagaraju3
1Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Faculty of Medicine and Health, The University of Sydney, Darlington, Australia.
附录腺癌 (AAs) 是罕见的. 系统化疗显著改善了阳性淋巴结的AA患者的存活率,特别是与细胞还原性手术和高热性腹膜内化疗 (HIPEC) 结合使用时.
科学领域:
- 手术瘤学手术瘤学
- 胃肠道瘤学 胃肠道瘤学
- 腹腔周围的恶性瘤
背景情况:
- 附录腺癌 (AAs) 是不常见的恶性瘤,倾向于腹转移 (PMs).
- 晚期呈现是常见的,需要评估治疗策略.
- 细胞还原性手术 (CRS) 与高热性腹腔内化疗 (HIPEC) 是一个关键的治疗方式.
研究的目的:
- 评估尾腺癌患者接受CRS治疗的结果.
- 确定全身化疗在管理PM的AA中的具体作用和益处.
- 评估影响AA患者生存的预后因素.
主要方法:
- 根据世卫组织2019年标准进行前性数据收集和分类.
- 评估细胞还原的完整性 (CC评分) 和HIPEC的管理 (米托米辛C).
- 使用卡普兰-梅尔和考克斯回归分析系统化疗时间 (前期,新辅助,辅助,缓解) 和生存率.
主要成果:
- 在216名患者中,有182名患者 (84%) 接受了CRS/HIPEC治疗,其中80%的患者达到CC0-1.
- 系统化疗给了队列中的45%,包括80%的淋巴结阳性患者.
- 平均整体生存时间为122个月. 阳性淋巴结从全身化疗中显著受益 (P < 0.0019).
结论:
- 带有阳性淋巴结的尾腺癌患者表现出系统化疗的最大益处.
- 腹癌的分期 (等级) 和非细胞性粘素的缺失是关键的预后指标.
- CRS/HIPEC为精选的AA患者提供了很好的结果,特别是那些患有较低级别腹疾病的患者.
更多相关视频
00:08Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
Published on: August 24, 2019
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
相关概念视频
Appendicitis-II: Diagnostic Studies and Management
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Appendicitis-I: Introduction
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
